NASDAQ:CTMX - CytomX Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.85 -0.83 (-3.23 %)
(As of 06/22/2018 08:00 AM ET)
Previous Close$25.68
Today's Range$24.60 - $25.68
52-Week Range$13.09 - $35.00
Volume275,000 shs
Average Volume485,535 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
CytomX Therapeutics logoCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio5.27
Quick Ratio5.27


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.62 million
Price / Sales13.52
Cash FlowN/A
Price / CashN/A
Book Value$1.82 per share
Price / Book13.65


EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-67.88%
Return on Equity-92.68%
Return on Assets-13.31%


Outstanding Shares38,960,000

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) issued its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.17. The biotechnology company earned $14.18 million during the quarter, compared to analysts' expectations of $19.77 million. CytomX Therapeutics had a negative return on equity of 92.68% and a negative net margin of 67.88%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

10 brokerages have issued twelve-month target prices for CytomX Therapeutics' stock. Their forecasts range from $37.00 to $44.00. On average, they anticipate CytomX Therapeutics' share price to reach $39.8571 in the next year. View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/10/2018)
  • 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
  • Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 40)
  • Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
  • Prof. Patrick S. Daugherty Ph.D., Founder and Member of Scientific Advisory Board
  • Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)

Has CytomX Therapeutics been receiving favorable news coverage?

News stories about CTMX stock have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a daily sentiment score of 0.24 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.45%), Millennium Management LLC (1.53%), FIL Ltd (1.10%), Redmile Group LLC (0.86%), Spark Investment Management LLC (0.75%) and American Century Companies Inc. (0.53%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Which major investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., American Century Companies Inc., Redmile Group LLC, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., JPMorgan Chase & Co. and Schroder Investment Management Group. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, Victory Capital Management Inc., FIL Ltd, Russell Investments Group Ltd., Federated Investors Inc. PA, Spark Investment Management LLC, EAM Global Investors LLC and Citadel Advisors LLC. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $24.85.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $1.00 billion and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]

MarketBeat Community Rating for CytomX Therapeutics (CTMX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.